Arsenal Biosciences Inc

ArsenalBio Inc. is a privately held company headquartered in South San Francisco, California. As a programmable cell therapy company, ArsenalBio employs 233 people and generates approximately $50 million in annual revenue. The company specializes in developing solid tumor cell therapies, utilizing a unique approach that combines CRISPR-enabled genome editing, logic gates for targeted tumor delivery, and therapeutic enhancements for multifaceted cancer attack. Their technology aims to improve efficacy and patient safety, while simultaneously reducing provider costs and expanding market access. ArsenalBio distinguishes itself through its programmable and computationally driven approach to cell therapy. This strategy allows for precise engineering of living medicines designed to combat the complex and multi-faceted nature of cancer. For more information about ArsenalBio and its innovative cancer therapies, please visit their website at arsenalbio.com.